Market News AIOpen the app

PMV Pharmaceuticals shared new results from its Phase 2 trial for rezatapopt, showing strong responses in patients with advanced tumors.

TrialRead the original at globenewswire.com
Good for PMVP

PMV reported a 48% confirmed response rate lasting a median 10.4 months in 65 ovarian cancer patients, supporting its planned 2027 application. Across 168 patients, the rate was 36% and response duration 8.1 months, but the planned filing focuses on ovarian cancer.

PMVP · PMV Pharmaceuticals

AI read · Good for PMVP

The AI's read

The ovarian-cancer findings give PMV evidence for its planned application. The wider group had lower response rates and shorter response times, so the strongest results remain tied to one cancer type. The application is planned for 2027, and no approval has been reported.

Get alerts for PMVP

Follow PMV Pharmaceuticals (PMVP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PMVP
Free on the App Store and Google Play, or on the web.